Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marco Russano

Showing results (1-10 of 71) with videos related to

Pageof 8
Sort By:
Recenti Progressi in Medicina|January 29, 2021
[Detection of novel driver mutations in liquid biopsy: case report of a RET-positive lung adenocarcinoma treated with pralsetinib.]Marco Russano
Oncotarget|September 24, 2017
Change from lung adenocarcinoma to small cell lung cancer as a mechanism of resistance to afatinibPaolo Manca, Marco Russano, Francesco Pantano, et al.
Experimental Hematology & Oncology|September 19, 2019
Cabozantinib and apixaban: an hitherto unreported interactionDaniele Santini, Fabrizio Citarella, Bruno Vincenzi, et al.
Future Oncology (London, England)|May 30, 2020
Facing SARS-CoV-2 outbreak in immunotherapy eraFabrizio Citarella, Marco Russano, Francesco Pantano, et al.
Recent Patents on Anti-Cancer Drug Discovery|August 7, 2015
"Impact of Smoking Cessation Treatment" on Lung Function and Response Rate in EGFR Mutated Patients: A Short-Term Cohort StudyAldo Pezzuto, Luciano Stumbo, Marco Russano, et al.
Studies in Health Technology and Informatics|May 24, 2024
Exploring Negated Entites for Named Entity Recognition in Italian Lung Cancer Clinical ReportsDomenico Paolo, Alessandro Bria, Carlo Greco, et al.
BMC Research Notes|May 14, 2015
Pazopanib and pancreatic toxicity: a case reportMarco Russano, Bruno Vincenzi, Olga Venditti, et al.
Expert Opinion on Biological Therapy|June 27, 2020
COVID-19 pneumonia and immune-related pneumonitis: critical issues on differential diagnosis, potential interactions, and managementMarco Russano, Fabrizio Citarella, Andrea Napolitano, et al.
Future Science OA|November 25, 2020
Steroid-refractory immune related hepatitis may hide viral re-activationFabrizio Citarella, Alessandro Galletti, Marco Russano, et al.
Critical Reviews in Oncology/Hematology|December 22, 2023
Clinical evidence and adverse event management update of patients with RET- rearranged advanced non-small-cell lung cancer (NSCLC) treated with pralsetinibGiuseppe Lo Russo, Paolo Bironzo, Chiara Bennati, et al.
Pageof 8

Showing results (1-10 of 71) with videos related to

Sort By:
Pageof 8
Recenti Progressi in Medicina|January 29, 2021
[Detection of novel driver mutations in liquid biopsy: case report of a RET-positive lung adenocarcinoma treated with pralsetinib.]Marco Russano
Oncotarget|September 24, 2017
Change from lung adenocarcinoma to small cell lung cancer as a mechanism of resistance to afatinibPaolo Manca, Marco Russano, Francesco Pantano, et al.
Experimental Hematology & Oncology|September 19, 2019
Cabozantinib and apixaban: an hitherto unreported interactionDaniele Santini, Fabrizio Citarella, Bruno Vincenzi, et al.
Future Oncology (London, England)|May 30, 2020
Facing SARS-CoV-2 outbreak in immunotherapy eraFabrizio Citarella, Marco Russano, Francesco Pantano, et al.
Recent Patents on Anti-Cancer Drug Discovery|August 7, 2015
"Impact of Smoking Cessation Treatment" on Lung Function and Response Rate in EGFR Mutated Patients: A Short-Term Cohort StudyAldo Pezzuto, Luciano Stumbo, Marco Russano, et al.
Studies in Health Technology and Informatics|May 24, 2024
Exploring Negated Entites for Named Entity Recognition in Italian Lung Cancer Clinical ReportsDomenico Paolo, Alessandro Bria, Carlo Greco, et al.
BMC Research Notes|May 14, 2015
Pazopanib and pancreatic toxicity: a case reportMarco Russano, Bruno Vincenzi, Olga Venditti, et al.
Expert Opinion on Biological Therapy|June 27, 2020
COVID-19 pneumonia and immune-related pneumonitis: critical issues on differential diagnosis, potential interactions, and managementMarco Russano, Fabrizio Citarella, Andrea Napolitano, et al.
Future Science OA|November 25, 2020
Steroid-refractory immune related hepatitis may hide viral re-activationFabrizio Citarella, Alessandro Galletti, Marco Russano, et al.
Critical Reviews in Oncology/Hematology|December 22, 2023
Clinical evidence and adverse event management update of patients with RET- rearranged advanced non-small-cell lung cancer (NSCLC) treated with pralsetinibGiuseppe Lo Russo, Paolo Bironzo, Chiara Bennati, et al.
Pageof 8